13:00 |
°³È¸¼±¾ð |
Ãæ³²ÀÇ´ë º´¸®Çб³½Ç °´ë¿µ(´ëȸÀå) |
|
13:00-13:20 |
Ûíߣ ÍÔóãâï ±³¼ö Ã߸ðÇà»ç |
|
|
13:20-14:50 |
Oral Presentation A |
ÁÂÀå: ¿¬¼¼ÀÇ´ë ³»°ú ÀÌÀºÁ÷/
°í½ÅÀÇ´ë À̺ñÀÎÈÄ°ú ÀÌ°´ë |
|
13:20-14:50 |
Oral Presentation B |
ÁÂÀå: ¿ï»êÀÇ´ë ¿µ»óÀÇÇаú ¹éÁ¤È¯ /
¼º±Õ°üÀÇ´ë ¿Ü°ú ±èÁö¼ö |
|
14:50-15:00 |
Coffee break |
|
|
15:00-16:30 |
Symposium A: Anaplastic thyroid cancer (¿µ¾î·Î ÁøÇà) |
ÁÂÀå: ¿¬¼¼ÀÇ´ë ³»°ú ±è°æ·¡ /
°¡ÃµÀÇ´ë ¿Ü°ú ÀÌ¿µµ· |
|
Anaplastic thyroid cancer: a therapeutic dilemma |
Hang-Seok Chang(Yonsei Univ. Korea) |
|
Novel treatment for anaplastic cancer with conventional drugs |
Hitoshi Noguchi
(Noguchi Thyroid Clinic and
Hospital Foundation, Beppu, Japan) |
|
Anaplastic thyroid cancer: a UK perspective |
Jonathan Wadsley
(Weston Park Hospital, UK) |
|
15:00-16:30 |
Symposium B: Dosimetric approach in radioactive iodine treatment |
ÁÂÀå: Àü³²ÀÇ´ë ÇÙÀÇÇаú ¹üÈñ½Â /
ÃæºÏÀÇ´ë ³»°ú ±Ã¼º¼ö |
|
Rationale of conventional fixed dose in radioiodine therapy |
¼øõÇâÀÇ´ë ÇÙÀÇÇаú ¹ÚÁ¤¹Ì |
|
Image based dosimetric evaluation of radionuclide therapy |
Çѱ¹¿øÀÚ·ÂÀÇÇпø ÇÙÀÇÇаú ÀÓÀÏÇÑ |
|
Radioiodine therapy based on dosimetric approach: method and efficacy |
¼¿ïÀÇ´ë ÇÙÀÇÇаú ÆØÁøö |
|
16:30-16:50 |
¹æ»ç¼º ¿ä¿Àµå Ä¡·á¿Í °ü·ÃµÈ ȯÀÚ ±³À°ÀÚ·á Á¦Á¤ º¸°í |
¿ï»êÀÇ´ë ³»°ú ±è¿ø¹è |
|
16:50-18:20 |
¿¬±¸ À§¿øȸ Seminar: È¿°úÀûÀÎ ÇÁ·¹Á¨Å×À̼ǹý |
¿ï»êÀÇ´ë À̺ñÀÎÈÄ°ú ÃÖ½ÂÈ£ |
|
Prezi¸¦ ÀÌ¿ëÇÑ story telling |
±¤Áֱ⵶º´¿ø À̺ñÀÎÈÄ°ú ¹Úº´Ã¶ |
|
½º¸¶Æ®-¿öÅ© ½Ã´ëÀÇ ÇÁ·¹Á¨Å×ÀÌ¼Ç µðÀÚÀÎ |
MS powerpoint MVP ±èÁöÈÆ |
|
16:50-18:20 |
¹æ»ç¼º ¿ä¿Àµå Ä¡·á ȯÀÚÀÇ ±³À° (½Ç¹«ÀÚ¸¦ À§ÇÑ ±³À°) |
ÁÂÀå: ¿ï»êÀÇ´ë ³»°ú ±è¿ø¹è |
|
¹æ»ç¼º ¿ä¿Àµå Ä¡·áÀÇ °³°ü°ú Ä¡·á¸¦ À§ÇÑ Áغñ »çÇ× |
¼¿ïÀÇ´ë ³»°ú ¹Ú¿µÁÖ |
|
¹æ»ç¼º ¿ä¿Àµå Ä¡·á½Ã ¹× Ä¡·á ÈÄ °ü¸® |
Áß¾ÓÀÇ´ë ÇÙÀÇÇаú ¼®ÁÖ¿ø |
|
¹æ»ç¼º ¿ä¿Àµå Ä¡·á¸¦ À§ÇÑ Àú¿ä¿Àµå ½Ä»ç¿ä¹ý |
°³²¼¼ºê¶õ½ºº´¿ø ¿µ¾çÆÀ ÀÌ¼Û¹Ì |
|
¹æ»ç¼º ¿ä¿Àµå Ä¡·á ȯÀÚ ±³À°ÀÇ ½ÇÁ¦ |
¼¿ï¾Æ»êº´¿ø ÇÙÀÇÇаú CNS À¯¼±Èñ |
|
08:00-9:30 |
Oral Presentation C |
ÁÂÀå: °¡Å縯ÀÇ´ë À̺ñÀÎÈÄ°ú ±è¹Î½Ä /
ºÎ»êÀÇ´ë ³»°ú ±èÀÎÁÖ |
|
08:00-9:30 |
Oral Presentation D |
ÁÂÀå: ¿¬¼¼ÀÇ´ë ¿Ü°ú Á¤¿õÀ± /
°í½ÅÀÇ´ë ³»°ú ÃÖ¿µ½Ä |
|
|
09:30-10:20 |
Plenary lecture: |
ÁÂÀå: ¿¬¼¼¿øÁÖÀÇ´ë ¿Ü°ú °¼ºÁØ
(´ëÇÑ°©»ó¼±ÇÐȸ ȸÀå) |
|
Noguchi Thyroid Clinic: 90 years of thyroid surgery and beyond |
Hitoshi Noguchi (Noguchi Thyroid Clinic and Hospital Foundation, Beppu, Japan) |
|
10:20-10:30 |
Coffee break |
|
|
10:30-12:00 |
Symposium C - Controversies in staging system |
ÁÂÀå: ¿¬¼¼ÀÇ´ë º´¸®°ú È«¼ø¿ø /
°¡Å縯´ë ¿Ü°ú ±èÁ¤¼ö |
|
Overview of staging system in thyroid cancer |
¿ï»êÀÇ´ë ¿Ü°ú Á¤±â¿í |
|
T stage: controversies and recent issues |
°æºÏÀÇ´ë º´¸®°ú ¹ÚÁö¿µ |
|
N stage: controversies and recent issues |
¼¿ïÀÇ´ë º´¸®°ú ¹ÎÇý¼÷ |
|
10:30-12:00 |
Symposium D - Molecular biology update in thyroidology |
ÁÂÀå: ¼¿ïÀÇ´ë ³»°ú ¹ÚµµÁØ /
Ãæ³²ÀÇ´ë ³»°ú ¼Û¹ÎÈ£ |
|
HIF-1 alpha¿Í Á¶Á÷Àú»ê¼ÒÁõ |
¿¬¼¼ÀÇ´ë À̺ñÀÎÈÄ°ú °íÀ±¿ì |
|
L1 ¼¼Æ÷ºÎÂø¹°Áú°ú ¾ÏÀÇ Áõ½Ä, À̵¿, ÀüÀÌ |
Ãæ³²ÀÇ´ë ³»°ú ±è±º¼ø |
|
¸é¿ª¼¼Æ÷¿Í ¾Ï¼¼Æ÷ÀÇ »óÈ£ÀÛ¿ë |
¼¿ïÀÇ´ë ³»°ú Á¶¼±¿í |
|
12:00-12:20 |
ÃÑȸ |
|
|
12:20-13:30 |
Lunch |
|
|
13:30-13:20 |
Special Lecture |
ÁÂÀå: ¼º±Õ°üÀÇ´ë ³»°ú Á¤ÀçÈÆ
(´ëÇÑ°©»ó¼±ÇÐȸ ÀÌ»çÀå) |
|
Multicentre randomized phase III clinical trial of high vs. low dose radioiodine, with or without recombinant
human thyroid stimulating hormone (rhTSH), for remnant ablation for
differentiated thyroid cancer: results of
the HiLo trial. |
Jonathan Wadsley(Consultant Clinical Oncologist, Sheffield Teaching Hospitals NHS Trust, Weston Park Hospital, UK)
|
|
14:20-15:20 |
Topic Highlights |
ÁÂÀå: °¡Å縯ÀÇ´ë ³»°ú À̱¤¿ì /
¼¿ïÀÇ´ë ¿Ü°ú À±¿©±Ô |
|
15:20-15:30 |
Coffee break |
|
|
15:30-16:00 |
Presidential Lecture |
ÁÂÀå: °¡Å縯ÀÇ´ë ³»°ú À̱¤¿ì |
|
|
¿¬¼¼¿øÁÖÀÇ´ë °¼ºÁØ
(´ëÇÑ°©»ó¼±ÇÐȸ ȸÀå) |
|
16:00-17:40 |
Panel discussion: |
ÁÂÀå: ¿¬¼¼ÀÇ´ë ¿Ü°ú ¹ÚÁ¤¼ö |
|
¾ÖÁ¤ÇÐ(¾Ö¸ÅÇÑ °ÍÀ» Á¤¸®ÇØÁÖ´Â ÇÐȸ) |
Panel: ¼Û¿µ±â(¿ï»êÀÇ´ë ³»°ú),
¼ÒÀÇ¿µ(¾ÆÁÖÀÇ´ë ¿Ü°ú),
Á¤±¤À±(°í·ÁÀÇ´ë À̺ñÀÎÈÄ°ú),
Á¤Áرâ(¼¿ïÀÇ´ë ÇÙÀÇÇаú ),
³ªµ¿±Ô(ÈÞ¸Õ¿µ»óÀÇÇм¾ÅÍ),
È«¼ø¿ø(¿¬¼¼ÀÇ´ë º´¸®°ú) |
|
17:40-18:00 |
½Ã»ó½Ä ¹× Æóȸ |
|